Navigation Links
Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease
Date:12/1/2011

SAN DIEGO, Dec. 1, 2011 /PRNewswire/ -- Ceregene, Inc. reported today that it has completed enrollment in its Phase 2b trial of CERE-120, a gene therapy product expressing the neurturin (NRTN) gene for the treatment of Parkinson's disease.  This Phase 2b study enrolled 51 patients at 11 medical centers throughout the United States.  CERE-120 is comprised of an AAV vector intended to provide constant, sustained expression of neurturin (NRTN), a neurotrophic factor shown to rescue dying dopaminergic neurons, restoring their function and protecting them from cell death.

Ceregene also reported that it has been chosen to present its work on CERE-120 at Windhover's annual Therapeutic Area Partnership conference as one of the "Top 10 Neuroscience Projects to Watch".  Raymond T. Bartus, Ph.D., Ceregene's executive vice president and chief scientific officer will present at the Boston conference on Thursday December 1st at 1:30 pm.

"Safely completing enrollment in our current Phase 2b CERE-120 Parkinson's study is an important milestone in Ceregene's history, as this study builds on the results of an earlier Phase 2 trial and is powered to demonstrate statistical significance of clinical benefit for CERE-120," stated Jeffrey M. Ostrove, Ph.D., Ceregene's president and chief executive officer.  "We have been fortunate to work with many of the world's leading Parkinson's disease experts in both the clinical trial design and implementation," noted Dr. Ostrove.

"The protocol and dosing scheme developed for the current study leveraged the unique and important insight we gained from the results of our previous clinical studies with CERE-120," noted Dr. Bartus. "Among other things, we observed a fundamental deficiency in the degenerating neurons of Parkinson's disease, which limits how effectively material, like NRTN, is transported from the terminals of these neurons to their cell bodies.  This provided the key insight required
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ceregene Advances Phase 2b CERE-120 (AAV2-neurturin) Trial in Parkinsons Disease
2. Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinsons Disease
3. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
4. ETCs Aircrew Training Systems Completes Factory Acceptance Tests for Highly Advanced Suite of Training Equipment for the Republic of Korea Air Force Aeromedical Center
5. Radient Pharmaceuticals Corporation Completes Restructurings with Institutional Investors to Limit Conversions and Stock Sales and Provide for Potential Additional Capital
6. Par Pharmaceutical Completes Acquisition of Anchen
7. Mylan Successfully Upsizes and Completes Refinancing of Credit Facility
8. New Spot Vision Screener Completes School Screening in Less Than Two Hours
9. MAQUET Cardiovascular Completes Acquisition of Atrium Medical Corporation
10. Global Pharm Holdings Group, Inc. Completes Acquisition of Qingdao Likang Pharmaceutical Co., Ltd.
11. Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Massachusetts and LONDON , August ... approach seamlessly connects ... continuum improving outcomes and the ...  (NYSE: PHG AEX: PHIA) today announced its presence at  ... latest cardiology solutions, including Heart Model A.I. , EchoNavigator and ...
(Date:8/27/2015)... 27, 2015  A recent study by Feucht ... compared the Arthrosurface HemiCAP® Wave implant, which is ... "onlay" design implant for isolated patellofemoral disease. While ... and pain scores, none of the patients in ... However, 53% of the patients in the "onlay" ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ ... in the commercial development of the company,s supplemental ... Smart Oxygen device, being developed by ieCrowd,s subsidiary ... a patient,s changing demand for oxygen based on ... 510 (k) submission for the Smart Oxygen device ...
Breaking Medicine Technology:Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4
... Israel, August 31, 2011 Elbit Imaging Ltd. ... for the second quarter of 2011. Consolidated revenues ... to NIS 241 million (US$ 71 million) compared to NIS 573 ... decrease is mainly attributable to: (i) we reported non-recurring gain from ...
... EXTON, Pa., Aug. 30, 2011 Kensey Nash Corporation ... at the following investor conferences in September. ... Growth Conference 2011 in Chicago on Wednesday, September 7th, ... company,s website ( www.kenseynash.com ) at 8:00 a.m. ET ...
Cached Medicine Technology:Elbit Imaging Ltd. Announces Second Quarter Results for 2011 2Elbit Imaging Ltd. Announces Second Quarter Results for 2011 3Elbit Imaging Ltd. Announces Second Quarter Results for 2011 4Elbit Imaging Ltd. Announces Second Quarter Results for 2011 5Elbit Imaging Ltd. Announces Second Quarter Results for 2011 6Elbit Imaging Ltd. Announces Second Quarter Results for 2011 7Elbit Imaging Ltd. Announces Second Quarter Results for 2011 8Elbit Imaging Ltd. Announces Second Quarter Results for 2011 9Elbit Imaging Ltd. Announces Second Quarter Results for 2011 10Kensey Nash Investor Conference Schedule 2
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College joined nine ... experience as part of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models ... the third Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United ... to celebrate children helping children, a thank you to the many creative and ... contributed to the United Methodist initiative to end malaria deaths. , The Columbus ...
(Date:8/28/2015)... ... August 28, 2015 , ... With the goal of furthering ... the second year to the Adams County Fairgrounds in Mendon, IL on May 30th, ... money to support music education in the underfunded school districts of Mendon and its ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... As ... from Merz, received FDA clearance for results that last for two years, the ... exciting news for patients who are looking for a long-lasting, effective solution for their ...
(Date:8/28/2015)... ... 2015 , ... Loved ones of a person suffering from ... dependency, may be able to find some hope in the latest video uploads ... addiction located in Western Michigan. Focusing on several different aspects of the powerful ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3
... The sickle cell trait could be a causealbeit rareof ... during football training, according to a scientific poster ... Cardiology (ACC) Scientific Sessions, April 1-3, in New Orleans. ... 8 percent of African-Americans in the U.S., has been ...
... Fla. A study published in Cancer Discovery, the ... debuting here at the AACR 102nd Annual Meeting 2011, ... in the tumor microenvironment may help researchers better target ... University of California, San Francisco, demonstrated that the level ...
... of a study presented at the AACR 102nd Annual Meeting ... that improving quality of life affects stress-related biological markers and ... that telomeres shorten and deteriorate with aging, but they are ... trying to understand the interconnections between the mind and the ...
... -- Researchers who sequenced the entire genomes of tumors ... mutations, most of which were unique to individual patients. ... predict breast cancer patient outcomes and to find new ... Louis and the Siteman Cancer Center. After sequencing ...
... Highly exciting new data presented today at the ... superior virological response in HCV patients of genotypes ... Pegylated Interferon-alpha (PegIFN-alpha-2a), the current standard of care ... so important because they show PegIFN-lambda could provide ...
... two compounds that inhibit two of the most frequently ... Phase I trial, according to data presented at the ... The research, presented by Johanna Bendell, M.D., ... GDC-0941, which inhibits PI3K. Bendell, director of Gastrointestinal ...
Cached Medicine News:Health News:Young black athletes with sickle cell trait might be susceptible to sudden death 2Health News:Immune system may guide chemotherapy for breast cancer 2Health News:Chronic stress of cancer causes accelerated telomere shortening 2Health News:Most Breast Tumors Have Unique Genetic 'Fingerprint,' Study Finds 2Health News:PegIFN-lambda shows superior virological response and improved safety than PegIFN-alpha-2a 2Health News:Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity 2
... Tecans MiniPrep series of robotic workstations ... The MiniPrep is the ideal automation ... automation of routine laboratory procedures, improving throughput, ... based Gemini for MiniPrep software allows you ...
... QFill2 is the ideal system for fast, accurate ... pressure driven, pinch valve controlled dispensing mechanism, ensures ... all of the components that come into contact ... clean, and autoclave. The unique compact design saves ...
... Automatic dispenser for low volumes. Dispenses ... 1536 -well format. Fast throughput of less ... productivity. The dispenser features an intuitive user ... be used to dispense liquids and suspensions, ...
... low volumes. Dispenses volumes down to 0.5ul ... throughput of less than 30 seconds per ... an intuitive user interface that provides one-button ... liquids and suspensions, beads, or cells, with ...
Medicine Products: